Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Viking Therapeutics Inc Market Cap
Based on ratings from 14 stock analysts, the Viking Therapeutics Inc stock price is expected to increase by 112.64% in 12 months. This is calculated by using the average 12-month stock price forecast for Viking Therapeutics Inc. The lowest target is $80 and the highest is $164. Please note analyst price targets are not guaranteed and could be missed completely.
Viking Therapeutics Inc has a total of 14 Wall St Analyst ratings. There are 14 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Viking Therapeutics Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of VKTX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Joseph Pantginis HC Wainwright & Co. | Buy | $102 | Reiterates | Nov 27, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $102 | Reiterates | Nov 26, 2024 |
| Mayank Mamtani B. Riley Securities | Buy | $109 | Initiates | Nov 22, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $102 | Maintains | Nov 5, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $90 | Reiterates | Oct 24, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $90 | Reiterates | Oct 9, 2024 |
| Jay Olson Oppenheimer | Outperform | $138 | Reiterates | Sep 25, 2024 |
| Michael Ulz Morgan Stanley | Overweight | $105 | Reiterates | Sep 12, 2024 |
| Hardik Parikh JP Morgan | Overweight | $80 | Initiates | Sep 11, 2024 |
| Steven Seedhouse Raymond James | Strong Buy | $118 | Maintains | Jul 25, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $90 | Reiterates | Jul 25, 2024 |
| Michael Ulz Morgan Stanley | Overweight | $105 | Initiates | Jun 27, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $90 | Reiterates | Jun 24, 2024 |
| Joon Lee Truist Securities | Buy | $120 | Maintains | Jun 17, 2024 |
| Steven Seedhouse Raymond James | Strong Buy | Reiterates | Jun 4, 2024 | |
| Naz Rahman Maxim Group | Buy | $120 | Reiterates | Jun 4, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $90 | Reiterates | Jun 4, 2024 |
| Steven Seedhouse Raymond James | Strong Buy | $116 | Upgrade | May 16, 2024 |
| Joon Lee Truist Securities | Buy | $120 | Reiterates | May 16, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $90 | Reiterates | Apr 25, 2024 |
When did it IPO
2015
Staff Count
30
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Brian Lian Ph.D.
Market Cap
$6.07B
In 2023, VKTX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that VKTX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 27 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Pomerantz LLP is investigating claims for investors of Viking Therapeutics, Inc. (NASDAQ:VKTX). Interested parties can contact Danielle Peyton for more information.
Why It Matters - Investigation into Viking Therapeutics may indicate potential legal issues or risks, impacting stock performance and investor confidence in the company.
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - Benzinga
Summary - The Biden-Harris Administration plans to expand Medicare and Medicaid coverage for anti-obesity medications, responding to criticism of high prices for drugs like Wegovy and Ozempic from Novo Nordisk.
Why It Matters - Proposed Medicare and Medicaid coverage expansion for anti-obesity drugs could increase demand for Novo Nordisk's products, impacting sales and stock performance amid pricing controversies.
Mon, 25 Nov 2024
Sentiment - POSITIVE
Source - The Motley Fool
Summary - Ken Griffin, founder of Citadel hedge fund since 1990, has seen his net worth reach $46 billion due to the fund's significant success.
Why It Matters - Ken Griffin's $46 billion net worth highlights Citadel's success, signaling strong performance in hedge fund management, which may attract more investors and influence market trends.
Sat, 23 Nov 2024
Sentiment - POSITIVE
Source - The Motley Fool
Summary - The news highlights three promising stocks that may have significant growth potential. Further details on the specific stocks and their performance are not provided.
Why It Matters - Identifying potential "monster stocks" indicates opportunities for significant growth, attracting investor interest and potentially driving market momentum and valuations upward.
Wed, 20 Nov 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - Viking Therapeutics presented final results from its VOYAGE Phase 2b trial of VK2809 for NASH at the American Association for the Study of Liver Disease.
Why It Matters - Viking Therapeutics' Phase 2b trial results for VK2809 could influence stock performance, investor sentiment, and future funding opportunities based on potential treatment efficacy for NASH.
Wed, 20 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Levi & Korsinsky is investigating Viking Therapeutics (NASDAQ:VKTX) for potential federal securities law violations following positive trial data for its anti-obesity drug VK2735, which boosted stock prices by 9%.
Why It Matters - The investigation into Viking Therapeutics for potential securities law violations could impact investor confidence, especially following the recent positive trial data and stock price surge.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
